Publications by authors named "Melissa Mcilraith"
Objective: This study aimed to expand the understanding of the patient with psoriatic arthritis (PsA) experience and to compare/contrast patient and clinician prioritization of PsA dimensions.
Methods: We conducted four patients with PsA focus groups across three US rheumatology practices using mixed methods to identify attributes of PsA important to patients. Combination with extant attributes of PsA identified by a steering committee created a comprehensive list of attributes.
Article Synopsis
- Long-term safety of adalimumab, an anti-TNF drug, was analyzed based on data from over 23,000 patients across multiple diseases including rheumatoid arthritis and Crohn's disease.
- The study found that infections were the most common serious adverse events, with overall malignancy and death rates similar to those in the general population, although some cancer rates were elevated in specific conditions.
- No new safety concerns were identified, indicating that adalimumab's safety profile remains consistent with what is already known about the anti-TNF class of medications.
Background: Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis.
Methods: Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with nonsteroidal antiinflammatory drugs underwent stratification according to methotrexate use and received 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for 16 weeks.